Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

ARS Pharmaceuticals (SPRY) Long-Term Debt Repayments: 2021-2022

Historic Long-Term Debt Repayments for ARS Pharmaceuticals (SPRY) over the last 2 years, with Dec 2022 value amounting to $6.0 million.

  • ARS Pharmaceuticals' Long-Term Debt Repayments rose 513.18% to $6.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was $8.7 million, marking a year-over-year change of. This contributed to the annual value of $8.7 million for FY2022, which is 377.77% up from last year.
  • ARS Pharmaceuticals' Long-Term Debt Repayments amounted to $6.0 million in Q4 2022, which was up 555.01% from $909,000 recorded in Q3 2022.
  • In the past 5 years, ARS Pharmaceuticals' Long-Term Debt Repayments ranged from a high of $6.0 million in Q4 2022 and a low of $350,000 during Q1 2021.
  • Its 2-year average for Long-Term Debt Repayments is $1.5 million, with a median of $909,000 in 2022.
  • Data for ARS Pharmaceuticals' Long-Term Debt Repayments shows a peak YoY spiked of 513.18% (in 2022) over the last 5 years.
  • Quarterly analysis of 2 years shows ARS Pharmaceuticals' Long-Term Debt Repayments stood at $971,000 in 2021, then soared by 513.18% to $6.0 million in 2022.
  • Its last three reported values are $6.0 million in Q4 2022, $909,000 for Q3 2022, and $910,000 during Q2 2022.